Advanced search
Publication Cover
Cancer Investigation Volume 29, 2011 - Issue 2
Submit an article Journal homepage
153
Views
22
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE: CLINICAL TRANSLATIONAL THERAPEUTICS

LMWH Bemiparin and ULMWH RO-14 Reduce the Endothelial Angiogenic Features Elicited by Leukemia, Lung Cancer, or Breast Cancer Cells

Alfonso VignoliDivision of Immunohematology and Transfusion Medicine, Department of Oncology-Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
,
Marina MarchettiDivision of Immunohematology and Transfusion Medicine, Department of Oncology-Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
,
Laura RussoDivision of Immunohematology and Transfusion Medicine, Department of Oncology-Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
,
Elena CantalinoDivision of Immunohematology and Transfusion Medicine, Department of Oncology-Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
,
Erika DianiDivision of Immunohematology and Transfusion Medicine, Department of Oncology-Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
,
Gaia BonacinaDivision of Immunohematology and Transfusion Medicine, Department of Oncology-Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
&
Anna FalangaDivision of Immunohematology and Transfusion Medicine, Department of Oncology-Hematology, Ospedali Riuniti di Bergamo, Bergamo, ItalyCorrespondence[email protected]
 show all
Pages 153-161 | Published online: 24 Jan 2011

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Anna Falanga, Alfonso Vignoli, Erika Diani & Marina Marchetti. (2011) Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival. Patient Related Outcome Measures 2, pages 175-188.
Read now

Articles from other publishers (21)

Marina Marchetti, Laura Russo, Cinzia Giaccherini, Sara Gamba & Anna Falanga. (2022) Hemostatic system activation in breast cancer: Searching for new biomarkers for cancer risk prediction and outcomes. Thrombosis Research 213, pages S46-S50.
Crossref
Chia Yin Goh, Sean Patmore, Albert Smolenski, Jane Howard, Shane Evans, Jamie O'Sullivan & Amanda McCann. (2021) The role of von Willebrand factor in breast cancer metastasis. Translational Oncology 14:4, pages 101033.
Crossref
Umer Ejaz, Fahad Akhtar, Jinbing Xue, Xinyu Wan, Tong Zhang & Shuying He. (2021) Review: Inhibitory potential of low molecular weight Heparin in cell adhesion; emphasis on tumor metastasis. European Journal of Pharmacology 892, pages 173778.
Crossref
D. Bіlyі, M. Rublenko, V. Samoiliuk & T. Spitsyna. (2020) Perspective directions of conservative treatment of bitches with breast tumors (review information). Naukovij vìsnik veterinarnoï medicini:2(160), pages 166-174.
Crossref
Amparo Santamaría & Milagros Suito. (2020) Efectos anticancerígenos de las heparinas. Medicina Clínica 154:10, pages 398-399.
Crossref
Amparo Santamaría & Milagros Suito. (2020) Antineoplastic effects of heparins. Medicina Clínica (English Edition) 154:10, pages 398-399.
Crossref
Mengying Zhang, Shuxie Wu & Chengping Hu. (2020) Do lung cancer patients require routine anticoagulation treatment? A meta-analysis. Journal of International Medical Research 48:1, pages 030006051989691.
Crossref
Xuemin Shen, Zhenfeng Liu, Junhui Li, Dongmei Wu, Meng Zhu, Lufeng Yan, Guizhu Mao, Xingqian Ye, Robert J. Linhardt & Shiguo Chen. (2019) Development of low molecular weight heparin by H2O2/ascorbic acid with ultrasonic power and its anti-metastasis property. International Journal of Biological Macromolecules 133, pages 101-109.
Crossref
Alfonso Vignoli, Marina Marchetti & Anna Falanga. (2018) Acute promyelocytic leukemia cell adhesion to vascular endothelium is reduced by heparins. Annals of Hematology 97:9, pages 1555-1562.
Crossref
Biagio Ricciuti, Jennifer Foglietta, Rita Chiari, Amirhossein Sahebkar, Maciej Banach, Vanessa Bianconi & Matteo Pirro. (2017) Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications. Medical Oncology 35:1.
Crossref
Alfonso Vignoli, Marina Marchetti & Anna Falanga. (2017) Heparins inhibit the endothelial pro-thrombotic features induced by tumor cells. Thrombosis Research 157, pages 55-57.
Crossref
Yishu Yan, Yang Ji, Nan Su, Xiang Mei, Yi Wang, Shanshan Du, Wenming Zhu, Chong Zhang, Yuan Lu & Xin-Hui Xing. (2017) Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: A review. Carbohydrate Polymers 160, pages 71-81.
Crossref
İhsan Alur, Yavuz Dodurga, Mücahit Seçme, Levent Elmas, Gülseren Bağcı, İbrahim Gökşin & Çığır Biray Avcı. (2016) Anti-tumor effects of bemiparin in HepG2 and MIA PaCa-2 cells. Gene 585:2, pages 241-246.
Crossref
Chris Tieken & Henri H. Versteeg. (2016) Anticoagulants versus cancer. Thrombosis Research 140, pages S148-S153.
Crossref
Jooho Park, Jee-Heon Jeong, Taslim A. Al-Hilal, Ji-young Kim & Youngro Byun. (2015) Size Controlled Heparin Fragment–Deoxycholic Acid Conjugate Showed Anticancer Property by Inhibiting VEGF 165 . Bioconjugate Chemistry 26:5, pages 932-940.
Crossref
Isabel Rodrigo, Sofía Caruncho, Concepción Alonso, Antonio Gómez-Outes & Barbara Mulloy. 2015. Non-Biological Complex Drugs. Non-Biological Complex Drugs 291 331 .
Marco Matteo Ciccone, Francesca Cortese, Filomena Corbo, Noel Ernesto Corrales, Abdul Kareem Al-Momen, Antonio Silva, Annapaola Zito, Mariangela Pinto, Michele Gesualdo & Pietro Scicchitano. (2014) Bemiparin, an effective and safe low molecular weight heparin: A review. Vascular Pharmacology 62:1, pages 32-37.
Crossref
Zhang Liu, Shengli Ji, Juzheng Sheng & Fengshan Wang. (2014) Pharmacological effects and clinical applications of ultra low molecular weight heparins. Drug Discoveries & Therapeutics 8:1, pages 1-10.
Crossref
R. Lecumberri, G. López Vivanco, A. Font, E. González Billalabeitia, A. Gúrpide, J. Gómez Codina, D. Isla, A. Galán, I. Bover, M. Domine, V. Vicente, R. Rosell & E. Rocha. (2013) Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Results from the ABEL study. Thrombosis Research 132:6, pages 666-670.
Crossref
Jeanine M. Walenga & Gary H. Lyman. (2013) Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: A review of pharmacologic and clinical differences and applications in patients with cancer. Critical Reviews in Oncology/Hematology 88:1, pages 1-18.
Crossref
Lia Ginaldi & Massimo De Martinis. 2012. Biotargets of Cancer in Current Clinical Practice. Biotargets of Cancer in Current Clinical Practice 159 194 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.